
Kennedy rattles food companies with vow to rid food of artificial dyes
And while Kennedy said in the meeting that he wanted to work with the industry, he also 'made clear his intention to take action unless the industry is willing to be proactive with solutions,' the association wrote.
Get Starting Point
A guide through the most important stories of the morning, delivered Monday through Friday.
Enter Email
Sign Up
'But to underscore, decision time is imminent,' Melissa Hockstad, who attended the meeting and is the group's president, wrote in the letter.
Advertisement
Later on Monday, Kennedy issued a directive that would also affect food companies nationwide. He ordered the Food and Drug Administration to revise a long-standing policy that allowed companies — independent of any regulatory review — to decide that a new ingredient in the food supply was safe. Put in place decades ago, the policy was aimed at ingredients like vinegar or salt that are widely considered to be well-understood and benign. But the designation, known as GRAS, or 'generally recognized as safe,' has since grown to include a far broader array of natural and synthetic additives.
Kennedy had vowed to upend the food system as a way to address growing rates of chronic disease and other health concerns even before his appointment as the head of the Department of Health and Human Services. He now oversees the FDA, the federal regulator for about 80 percent of the nation's food supply.
Many food companies rely on artificial dyes to make breakfast cereals and candies dazzling shades of pink and blue, for instance, or beverages neon orange. Some have tried to adapt natural ingredients, like carrot or blueberry juice, for coloring, particularly for products sold in international markets. But the companies have said that consumer demand had weakened in the United States because of dissatisfaction with less appealing or vivid colors in snacks and drinks.
Advertisement
Steven Williams, chief executive of PepsiCo's North America division, attended the meeting with Kennedy, but the company said he would not comment. In an email, a PepsiCo spokesperson said that the company viewed the meeting as a 'productive first step' and added it was focused on providing consumers 'more options with natural ingredients, no synthetic colors and reductions in sugar, fat and sodium.'
Stacy Flathau, the chief corporate affairs officer for WK Kellogg, said in an emailed statement that the company looked forward to working with the new administration.
While the industry memo expressed alarm about the plan to remove synthetic colors, it did not address Kennedy's additional proposal targeting some food ingredients deemed safe.
Advocates for food safety have criticized the existing GRAS policy as a loophole enabling food companies to introduce untested ingredients that in some cases have proved hazardous. About 1,000 ingredients deemed safe have been reviewed by the FDA, but Kennedy targeted the ones that companies deem acceptable with no government oversight.
'Eliminating this loophole will provide transparency to consumers, help get our nation's food supply back on track by ensuring that ingredients being introduced into foods are safe, and ultimately Make America Healthy Again,' Kennedy said in a statement.
Bills to remove synthetic colors from the food supply have taken off since California banned Red Dye No. 3, a move that the FDA followed. Other state proposals have targeted titanium dioxide, a compound used to make food appear shiny. Texas and West Virginia have moved to strip colorants from some school lunches.
Advertisement
In Hockstad's letter to food company executives, she said Kennedy wanted synthetic color additives known as FD&C colors, or Food, Drug & Cosmetic dyes, removed during his administration.
Vani Hari, an activist known online as the Food Babe who did not attend the meeting, applauded Kennedy's willingness to take on the food industry. 'Bobby gave the food industry an ultimatum,' she said. 'Either work with us to make these changes happen, or we'll do it ourselves.'
Stuart Pape, a lawyer who represents food companies, said Kennedy's plan was 'ambitious.' He said the FDA traditionally had proposed removal of one coloring at a time, presenting research on why the ingredient was unsafe. Whether there is an adequate supply of alternative colorings would be a concern of a broader plan.
'I think Kennedy has made no secret that he intends to go after the food ingredients,' Pape said. 'And I think this is the opening of that war.'
This article originally appeared in

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Associated Press
18 minutes ago
- Associated Press
Felycin®-CA1 (sirolimus delayed-release tablets) Redefines Feline Cardiac Care
First-in-class oral management option for hypertrophic cardiomyopathy earns FDA conditional approval, changing the landscape of feline medicine PENSACOLA, Fla., June 12, 2025 /PRNewswire/ -- Pegasus Laboratories/PRN Pharmacal has announced the addition of a new FDA conditionally approved drug, Felycin®-CA1 (sirolimus delayed-release tablets), to their portfolio. This first-in-class therapy is designed to manage ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy (HCM), representing a major milestone in feline medicine and offering new hope to owners of cats living with this progressive and often fatal disease. HCM is a heart condition which causes the muscular walls of a cat's heart to become abnormally thick, reducing the heart's ability to pump blood efficiently. This can lead to heart failure and other complications, including sudden death. Many cats with HCM remain subclinical for years, while others may develop symptoms of congestive heart failure. While the exact cause of the disease is not fully understood, HCM is more common in certain breeds, including British Shorthair, Chartreux, Maine Coon, Persian, Ragdoll, and Sphynx cats. Researchers have also identified mutations in various cardiac genes causing HCM in several of these breeds. 'Felycin-CA1 signals a turning point in feline medicine by providing veterinarians a much-needed option to help slow the progression of HCM beyond just managing the disease,' said Dr. Heather Davis, DVM, PhD, DACVS-LA, Director of Clinical Affairs and Veterinary Services at Pegasus Laboratories. 'It is a major step forward for cats and the people who care for them. For the first time, we're changing the conversation around what's possible in feline heart care.' FDA conditional approval of Felycin®-CA1 follows results from a multi-center study demonstrating its ability to improve key cardiac outcomes, while also proving its ease of use in everyday veterinary practices. 'Veterinarians have long-needed options beyond palliative care when it comes to feline HCM,' said Dr. Joshua Stern, DVM, PhD, DACVIM. 'With Felycin-CA1, we can offer a therapy that has been shown in our initial clinical trial to stop progressive heart muscle thickening, slowing disease progression. We believe this management option marks the beginning of a new chapter where innovation in feline therapeutics becomes the rule, not the exception.' Felycin®-CA1 is slated to be available beginning August 2025, in 0.4 mg, 1.2 mg, and 2.4 mg tablet strengths by prescription from a licensed veterinarian. Cats should be screened for pre-existing liver disease before starting the medication, and it should not be used in cats with pre-existing liver disease or diabetes mellitus. About Pegasus Laboratories Pegasus Laboratories, Inc., based in Pensacola Florida, is a pharmaceutical development and manufacturing organization focused on innovative products to treat chronic conditions in cats, dogs, and horses. Our products go to market under the PRN® Pharmacal brand. We also serve as a contract manufacturer for the Animal Health industry. We were founded in 1985 and acquired by PBI-Gordon Companies, Inc. in 1999. View original content to download multimedia: SOURCE Pegasus/PRN Pharmacal


CNN
26 minutes ago
- CNN
Newly approved antibody could offer another option for protecting infants from RSV, a common infection that can be deadly
The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that's the No. 1 cause of hospitalization in infants. The US Food and Drug Administration has approved a new monoclonal antibody to help prevent infection, according to an announcement late Monday from drugmaker Merck. Enflonsia is designed to be given in a single 105-milligram shot to protect newborns and infants from mild, moderate or severe RSV through all five months of their first virus season, which typically starts in the fall and goes through the next spring. Study materials that Merck submitted to the FDA for its approval showed that the antibody had a similar safety profile as a placebo. The most common adverse reactions from Enflonsia were mild and included injection-site swelling and a rash in a small number of infants. In a mid- to late-stage trial, Enflonsia reduced RSV-associated hospitalizations in infants more than 84% compared with a placebo. RSV can sometimes turn into serious lower respiratory infections like pneumonia, but the shot also reduced lower respiratory infections that needed medical attention by more than 60% compared with a placebo. 'Enflonsia provides an important new preventive option to help protect healthy and at-risk infants born during or entering their first RSV season,' Dr. Dean Y. Li, president of Merck Research Laboratories, said in a news release. 'We are committed to ensuring availability of Enflonsia in the US before the start of the upcoming RSV season to help reduce the significant burden of this widespread seasonal infection on families and health care systems.' Merck says it hopes Enflonsia will be available before the start of the 2025-26 respiratory virus season. First, it needs to be recommended by the US Centers for Disease Control and Prevention, and that means going in front of the agency's Advisory Committee on Immunization Practices. It's on the agenda for the panel's meeting this month, but US Health and Human Services Secretary Robert F. Kennedy removed all the members of that committee Monday. He says he will appoint new ones, but it's unclear how long that process will take. Doctors say another tool to prevent RSV cannot come soon enough. RSV is ubiquitous, one of the most common causes of childhood illness. Most kids will catch this highly contagious respiratory virus at some point before they turn 2, according to the CDC. For many healthy adults and older kids, RSV causes a mild illness like a cold. Typically, symptoms can be managed at home, and they often go away on their own. But for infants and the elderly, it can be a different story. Very young children's immune systems are just starting to learn how to fight infections, and infants have tiny airways. RSV inflames those airways, making it difficult to breathe, and can turn into a serious lower respiratory illness like bronchiolitis or pneumonia. Some of these RSV infections can be deadly. Two to three percent of infants under 6 months are hospitalized with RSV in the US every year, according to the CDC. Among children younger than 5, about 58,000 to 80,000 are hospitalized due to RSV. There's no specific medicine to treat RSV. Doctors can give an infant supportive care and oxygen, and then they essentially wait until their oxygen levels get back to normal, said Dr. Amy Edwards, director of pediatric infection control at UH Rainbow Babies and Children's Hospital in Cleveland. 'I hate RSV,' said Edwards, who was not connected with the Merck trial. 'Just to watch them struggle to breathe, and then they get scared, and then they cry, which of course makes the breathing worse, and their little lips turn blue. It's just so hard to watch.' Enflonsia joins a handful of other tools recently made available to protect babies from, although the FDA put RSV vaccine trials involving infants and young children ages 2 to 5 on hold last year after some developed severe illness. To prevent RSV in infants, the CDC currently recommends an RSV antibody made by Sanofi and AstraZeneca, called Beyfortus, which was approved in 2023. It was in short supply during that year's RSV season, although Edwards said supply started to catch up with demand in her health care system last season, and the company pledged to produce more. The other option to protect an infant is a vaccine that a person can get during pregnancy. Together, Beyfortus and the vaccine have made a difference. A CDC study published in March found that RSV-associated hospitalization rates among infants up to 7 months during 2024-25 season were lower than in seasons when those things weren't available. Edwards just hopes people will get protection for their infants. 'Every RSV season fills us to the gills,' she said. 'This should theoretically empty us out, if we have good uptake.' Correction: A previous version of this story incorrectly described the newly approved monoclonal antibody as a therapy.
Yahoo
32 minutes ago
- Yahoo
Analysis-Kennedy's ouster of US vaccine advisers puts pharma ties under scrutiny
By Chad Terhune (Reuters) -U.S. Health Secretary Robert F. Kennedy Jr.'s surprise ouster of a national vaccine advisory board, claiming it was "plagued with persistent conflicts of interest," puts new scrutiny on the group that recommends which shots should be administered to the American public. Kennedy said most vaccine experts on the 17-member Advisory Committee on Immunization Practices (ACIP) have received "substantial funding" from drugmakers. He did not provide examples of conflicts of interest for any individual adviser or say how that may have influenced specific recommendations. Committee members say their work with the U.S. Centers for Disease Control and Prevention follows rigorous vetting of their financial ties. They must abstain from votes on any vaccine for which they have a conflict, as well as any rival to that vaccine or any product from the same manufacturer, according to CDC rules. The agency's website lists one of the departing panel members as recusing herself over such conflicts. "To determine that the whole (advisory board), all 17 members, have conflicts of interest, that has not been shown by the evidence," fired board member Dr. Oliver Brooks told Reuters. "However, the decisions that have been made (by Kennedy) undermine confidence in the process and in vaccines." Six of the vaccine advisers fired by Kennedy received a total of $80 or less from drugmakers from 2017 to 2023, according to a Reuters review of the Open Payments federal database of industry payments to healthcare providers. Seven other panel members received between $4,000 and $55,000 from drugmakers for consulting, speaking fees, travel or meals over the period 2017 to 2023. Two of those experts had also worked with other scientists in industry-funded research projects worth several millions of dollars. Brooks, retired chief medical officer at Watts Healthcare in Los Angeles and former president of the National Medical Association, received nearly $44,000 in general payments from Sanofi, according to the government records. Most of the payments occurred in 2017 and 2018, with nothing after 2020. Brooks became a vaccine adviser in 2021, and did not disclose any conflicts that would preclude him from voting. He said the panel's sole aim is "to prevent vaccine-preventable illness." Sanofi declined to comment. At least three vaccine advisers were not health professionals tracked by mandatory Open Payments reporting. KENNEDY'S CONFLICT Kennedy, who has spent years sowing doubts about vaccine safety and efficacy contrary to scientific evidence, faced questions from Congress about his own potential conflicts of interest during a confirmation hearing. Kennedy said he would divest his financial interest in litigation against Merck over its Gardasil vaccine, which prevents cancers caused by the human papillomavirus, to his non-dependent, adult son. In posts on X this week, Kennedy said he would share "examples of the historical corruption at ACIP" and announced eight new panel members. Four of them had received nominal reimbursement for meals, according to Open Payments, while the remainder recorded no payments or weren't covered by the database. A 2009 federal inspector general's report criticized the CDC for lax enforcement of disclosures among its advisory panels. New research shared with Reuters suggests conflicts have since declined among vaccine board members. "People are more aware of these issues on advisory committees, so they're facing greater scrutiny there," said Dr. Genevieve Kanter, an associate professor of public policy at the University of Southern California who has studied conflicts among government health advisers. Kanter's analysis of vaccine panel disclosures found that, on average, 43% of panel members facing decisions on specific vaccines declared conflicts in 2000 compared to 5%, on average, at meetings over the last 10 years. Kanter said it will also be important to understand how the vaccine advisers assembled by Kennedy are vetted for conflicts. They are due to meet at the end of June. "We don't want to replace one conflict with another set of conflicts," she said. "If someone has a financial interest in treatments that are believed to be alternatives to vaccines for certain conditions, we want to know that." DISCLOSURE RULES ACIP members are required to divest all stock in vaccine makers and stop any active consulting work for those companies before joining the panel. They can't accept travel or food from vaccine companies or collect product royalties. Similar restrictions apply to family members. Committee members can keep working on vaccine clinical trials funded by industry and those research grants can help cover their salaries. They are required to file annual disclosures and recuse themselves from votes when specific conflicts arise. "ACIP members ... are carefully screened for major conflicts of interest and selected through a lengthy process," said the California Department of Public Health, whose immunization chief, Dr. Robert Schechter, was fired from the panel by Kennedy. One of the fired panel members, Dr. Bonnie Maldonado, is a pediatric infectious diseases specialist at Stanford University who has led vaccine studies worldwide. She participated in research that received $4.65 million in funding from Pfizer, most of it spanning 2021 to 2023. The studies involved vaccines for COVID-19, RSV and other diseases. Maldonado also received general payments from drugmakers, including $26,465 from Pfizer and nearly $7,000 from Merck. Maldonado abstained from a vote on COVID vaccine recommendations in June 2024, declaring a conflict of interest. In October, she did participate in a COVID-related vote. Maldonado didn't respond to a request for comment. Noel Brewer, a professor of public health at the University of North Carolina, is not a clinician and therefore not included in Open Payments. In a 2017 research paper, he disclosed receiving research grants from Merck, Pfizer and GSK and serving on a paid advisory board for Merck. The disclosures did not give details on the payment amounts. Spokespeople for the three vaccine makers were not immediately available for comment.